Early Aspirin Withdrawal After PCI in ACS: NEO-MINDSET and TARGET Trials
Christopher Cannon, Senior Physician in the Cardiovascular Division at Brigham and Women’s Hospital, shared a post on LinkedIn:
”Keep the ASA for the first 12 months post ACS PCI.
The NEO-MINDSET trial found that early stopping and keeping P2Y12 monotherapy was NOT sufficient for efficacy.
Of note, another study published, the TARGET First looked at “low risk” STEMI patients and suggested one could stop ASA, but it appeared to have much less power with just 41 primary endpoints.
So – I will aim to keep DAPT for a year post PCI for ACS. (although sometimes one has to adapt for very high risk bleeding patients).”
Title: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes
Authors: Patricia O. Guimarães, Marcelo Franken, Caio A.M. Tavares, Murillo O. Antunes, Fabio S. Silveira, Pedro B. Andrade, Ricardo R. Bergo
Read the full article here.
Find more on Hemostasis Today.
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH
-
Jan 8, 2026, 03:47Wolfgang Miesbach on Fernando Corrales-Medina’s Team’s Latest Cross-Sectional Study on Haemophilia
-
Jan 8, 2026, 03:28Rick Matthews: Powerful Perspective from Erin and the NBCA Team